CatalYm today announced that the first patient has been dosed in the Phase 2/3 VINCIT trial (Visugromab IN Cachexia ...

The dietary supplement melatonin does not improve the symptoms of cachexia in patients with advanced cancer, according to a study published online February 25 in the Journal of Clinical Oncology.

New research in fruit flies suggests that a decreased desire to eat protein can serve as the earliest known warning sign of ...

Curanex Pharmaceuticals Inc. CURX on Monday said that a recent patient case study may reinforce its strategic push into cancer cachexia, a severe wasting condition tied to advanced cancers with ...

Understanding the importance of using the right diagnostic criteria for cachexia is crucial, as it can significantly influence the health and survival of cancer patients. Maintaining good health and ...

Pfizer researchers say they are developing a drug that might counteract a condition that leads to the death of cancer patients within a year of its diagnosis. Photo by Stephanie Lecocq/EPA-EFE Sept.

Study met primary endpoint of change from baseline in body weight for ponsegromab compared to placebo across all ponsegromab doses tested, reaching 5.6% mean increase at the highest dose evaluated at ...

LONDON--(BUSINESS WIRE)--Technavio has been monitoring the cancer cachexia therapeutics market and it is poised to grow by USD 568.85 million during 2019-2023, progressing at a CAGR of 6% during the ...

Dublin, March 30, 2026 (GLOBE NEWSWIRE)-- The "Cancer Cachexia Market Report 2026" has been added to ResearchAndMarkets.com's offering. The report provides critical insights, including market size ...